Top

Published in:

Open Access 01-11-2007 | Chronic Diseases

The Rotterdam Study: objectives and design update

Authors: Albert Hofman, Monique M. B. Breteler, Cornelia M. van Duijn, Gabriel P. Krestin, Huibert A. Pols, Bruno H. Ch. Stricker, Henning Tiemeier, André G. Uitterlinden, Johannes R. Vingerling, Jacqueline C. M. Witteman

Published in: European Journal of Epidemiology | Issue 11/2007

Abstract

The Rotterdam Study is a prospective cohort study ongoing since 1990 in the city of Rotterdam in the Netherlands. The study targets cardiovascular, neurological, ophthalmological and endocrine diseases. As of 2008 about 15,000 subjects aged 45 years or over comprise the Rotterdam Study cohort. The findings of the Rotterdam Study have been presented in some 600 research articles and reports (see http://www.epib.nl/rotterdamstudy). This article gives the reasons for the study and its design. It also presents a summary of the major findings and an update of the objectives and methods.

Oeppen J, Vaupel JW. Broken limits to life expectancy. Science 2002;296:1029–31.PubMedCrossRef

Peto R, Doll R. There is no such thing as aging. BMJ 1997;315:1030–2.PubMed

Hofman A, Grobbee DE, de Jong PTVM, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Study. Eur J Epidemiol 1991;7:403–22.PubMedCrossRef

Hak AE, Pols HAP, Visser TJ, Drexhage HA, Hofman A, Witteman JCM. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med 2000;132:270–8.PubMed

Schuit SCE, Oei HHS, Witteman JCM, Geurts Van Kessel CH, Van Meurs JBJ, Nijhuis RL, Van Leeuwen JPTM, De Jong FH, Zillekens MC, Hofman A, Pols HAP, Uitterlinden AG. Estrogen receptor α gene polymorphisms and risk of myocardial infarction. JAMA 2004;291:2969–77.PubMedCrossRef

Kardys I, De Maat MP, Uitterlinden AG, Hofman A, Witteman JC. C-reactive protein gene haplotypes and risk of coronary heart disease. The Rotterdam Study. Eur Heart J 2006;27:1331–7.PubMedCrossRef

Oei HH, Van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MM, Witteman JC. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 2005;111:570–5.PubMedCrossRef

Kardys I, Klaver CC, Despriet DD, Bergen AA, Uitterlinden AG, Hofman A, Oostra BA, Van Duijn CM, De Jong PT, Witteman JC. A common polymorphism in the complement factor H gene is associated with increased risk of myocardial infarction. The Rotterdam Study. J Am Coll Cardiol 2006;47:1568–75.PubMedCrossRef

Van der Meer IM, Bots ML, Hofman A, del Sol AI, van der Kuip DA, Witteman JC. Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam Study. Circulation 2004;109:1089–94.PubMedCrossRef

10.

Mattace-Raso FUS, Van der Cammen TJM, Hofman A, Van Popele NM, Bos ML, Schalekamp MADH, Asmar R, Reneman RS, Hoeks A, Breteler MMB, Witteman JCM. Arterial stiffness and risk of coronary heart disease and stroke. The Rotterdam Study. Circulation 2006;113:657–63.PubMedCrossRef

11.

Vliegenthart R, Oudkerk M, Hofman A, Oei HHS, van Dijck W, van Rooij F, Witteman JCM. Coronary calcification improves cardiovascular risk prediction in a population of older adults. Circulation 2005;112:572–7.PubMedCrossRef

12.

Bleumink GS, Knetsch AM, Sturkenboom MC, Straus SM, Hofman A, Deckers JW, Witteman JC, Stricker BH. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure the Rotterdam Study. Eur Heart J 2004;25:1614–9.PubMedCrossRef

13.

Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, Stijnen T, Lip GY, Witteman JC. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27:949–53.PubMedCrossRef

14.

Heeringa J, van der Kuip DAM, Hofman A, Kors JA, van Rooij FJA, Lip GYH, Witteman JCM. Subclinical atherosclerosis and risk of atrial fibrillation. Arch Intern Med 2007;167:382–7.PubMedCrossRef

15.

Van Vark LC, Kardys I, Bleumink GS, Knetsch AM, Deckers JW, Hofman A, Stricker BH, Witteman JC. Lipoprotein-associated phospholipase A2 activity and risk of heart failure: the Rotterdam study. Eur Heart J 2006;27:2346–52.PubMedCrossRef

16.

Ott A, Breteler MMB, van Harskamp F, Claus JJ, van der Cammen TJM, Grobbee DE, Hofman A. Prevalence of Alzheimer’s disease and vascular dementia: association with education. The Rotterdam study. BMJ 1995;310:970-3.PubMed

17.

de Rijk MC, Breteler MMB, Graveland GA, Ott A, Grobbee DE, van der Meché FGA, Hofman A. Prevalence of Parkinson’s disease in the elderly. The Rotterdam Study. Neurology 1995;45:2143-6.PubMed

18.

Ruitenberg A, Ott A, van Swieten JC, Hofman A, Breteler MMB. Incidence of dementia: does gender make a difference? Neurobiol Aging 2001;22:575–80.PubMedCrossRef

19.

de Lau LML, Giesbergen PCLM, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MMB. Incidence of parkinsonism and Parkinson’s disease in a general population: the Rotterdam Study. Neurology 2004;63:1240–4.PubMed

20.

Hollander M, Koudstaal PJ, Bots ML, Grobbee DE, Hofman A, Breteler MMB. Incidence, risk and case fatality of first ever stroke in the elderly population. The Rotterdam Study. J Neurol Neurosurg Psychiatry 2003;74:317–21.PubMedCrossRef

21.

Breteler MMB, Claus JJ, Grobbee DE, Hofman A. Cardiovascular disease and the distribution of cognitive function in an elderly population. The Rotterdam Study. BMJ 1994;308:1604–8.PubMed

22.

Hofman A, Ott A, Breteler MMB, Bots ML, Slooter AJC, van Harskamp F, van Duijn CM, van Broeckhoven C, Grobbee DE. Atherosclerosis, apolipoprotein E and the prevalence of dementia and Alzheimer’s disease in the Rotterdam Study. Lancet 1997;349:151–4.PubMedCrossRef

23.

Ott A, Slooter AJC, Hofman A, van Harskamp F, Witteman JCM, van Broeckhoven C, van Duijn CM, Breteler MMB. Smoking and risk of dementia and Alzheimer’s disease in a population-based cohort study: the Rotterdam Study. Lancet 1998;351:1840–3.PubMedCrossRef

24.

Engelhart MJ, Geerlings MI, Ruitenberg A, van Swieten JC, Hofman A, Witteman JCM, Breteler MMB. Dietary intake of antioxidants and risk of Alzheimer’s disease: the Rotterdam Study. JAMA 2002;287:3223–9.PubMedCrossRef

25.

Ruitenberg A, van Swieten JC, Witteman JCM, Mehta KM, van Duijn CM, Hofman A, Breteler MMB. Alcohol consumption and risk of dementia: the Rotterdam Study. Lancet 2002;359:281–6.PubMedCrossRef

26.

In ‘t Veld BA, Ruitenberg A, Launer LJ, van Duijn CM, Hofman A, Stijnen Th, Breteler MMB, Stricker BHCh. NSAID and the risk of Alzheimer’s disease or vascular dementia. The Rotterdam Study. N Engl J Med 2001;345:1515–21.

27.

Hollander M, Bots ML, Iglesias del Sol A, Koudstaal PJ, Witteman JCM, Grobbee DE, Hofman A, Breteler MMB. Carotid plaques increase the risk of stroke and subtypes of cerebral infarction in asymptomatic elderly: the Rotterdam Study. Circulation 2002;105:2872–7.PubMedCrossRef

28.

Bos MJ, Schipper CMA, Koudstaal PJ, Witteman JCM, Hofman A, Breteler MM. High plasma C-reactive protein level is not an independent predictor for stroke. The Rotterdam Study. Circulation 2006;114:1591–8.PubMedCrossRef

29.

Vermeer SE, den Heijer T, Prins ND, Hofman A, Koudstaal PJ, Breteler MMB. Silent brain infarcts and the risk of dementia and cognitive decline. The Rotterdam Scan Study. N Engl J Med 2003;348:1215–22.PubMedCrossRef

30.

Vernooij MW, Ikram MA, Tanghe HL, Vincent AJPE, Hofman A, Krestin GP, Niessen WJ, Breteler MMB, Van der Luyt A. Incidental findings on brain MRI in the general population N Engl J Med 2007 (in press).

31.

de Groot JC, de Leeuw FE, Oudkerk M, Hofman A, Jolles J, Breteler MMB. Cerebral white matter lesions and depressive symptoms in elderly adults. Arch Gen Psychiatry 2000;57:1071–6.PubMedCrossRef

32.

Den Heijer T, Geerlings MI, Hoebeek FE, Hofman A, Koudstaal PJ, Breteler MMB. Use of hippocampal and amygdalar volumes on MRI to predict dementia in cognitively intact elderly people. Arch Gen Psychiatry 2006;63:57–62.CrossRef

33.

Breteler MMB, van Swieten JC, Bots ML, Grobbee DE, Claus JJ, van den Hout JHW, van Harskamp F, Tanghe HLJ, de Jong PTVM, van Gijn J, Hofman A. Cerebral white matter lesions, vascular risk factors and cognitive function in a population-based study. Neurology 1994;44:1246-52.PubMed

34.

Tiemeier H, Dijck van W, Hofman A, Witteman JCM, Stijnen T, Breteler MMB. Atherosclerosis and late life depression are related. The Rotterdam Study. Arch Gen Psychiatry 2004;61:369–76.PubMedCrossRef

35.

Tiemeier H, Bakker SLM, Hofman A, Koudstaal PJ, Breteler MMB. Cerebral haemodynamics and depression in the elderly. J Neurol Neurosurg Psychiatry 2002;73:34–39.PubMedCrossRef

36.

Naarding P, Tiemeier H, Breteler MM, Schoevers RA, Jonker C, Koudstaal PJ, Beekman AT. Clinically defined vascular depression in the general population. Psychol Med 2007;37:383–92.PubMedCrossRef

37.

Tiemeier H, van Tuijl HR, Hofman A, Kiliaan AJ, Breteler MMB. Plasma fatty acid composition and depression in the elderly are associated: the Rotterdam Study. Am J Clin Nutr 2003;78:40–6.PubMed

38.

Tiemeier H, van Tuijl HR, Hofman A, Meijer J, Kiliaan AJ, Breteler MMB. Vitamin B12, folate, and homocysteine in depression: the Rotterdam Study. Am J Psychiatry 2002;159:2099–101.PubMedCrossRef

39.

Tiemeier H, Hofman A, Kiliaan AJ, Meijer J, Breteler MMB. Vitamin E and depressive symptoms are not related. The Rotterdam Study. J Affect Disord 2002;72:79–83.CrossRef

40.

Tiemeier H, Hofman A, van Tuijl HR, Kiliaan AJ, Meijer J, Breteler MMB. Inflammatory proteins and depression in the elderly. Epidemiology 2003;14:103–7.PubMedCrossRef

41.

Tiemeier H, Schuit SC, den Heijer T, van Meurs JB, van Tuijl HR, Hofman A, Breteler MM, Pols HA, Uitterlinden AG. Estrogen receptor alpha gene polymorphisms and anxiety disorder in an elderly population. Mol Psychiatry 2005;10:806–7.PubMedCrossRef

42.

Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385–410.CrossRef

43.

Wing JK, Babor T, Brugha T, Burke J, Cooper JE, Giel R. Scan: schedules for clinical assessment in neuropsychiatry. Arch Gen Psychiatry 1990;47:589–93.PubMed

44.

Wittchen HU, Lachner G, Wunderlich U, Pfister H. Test-retest reliability of the computerized DSM-IV version of the Munich-Composite International Diagnostic Interview (M-CIDI). Soc Psychiatry Psychiatr Epidemiol 1998;33:568–78.PubMedCrossRef

45.

van den Berg JF, Tulen JHM, Neven AK, Hofman A, Miedema HME, Witteman JCM, Tiemeier H. Sleep duration and hypertension are not associated in the elderly. Hypertension 2007;50:585–9.PubMedCrossRef

46.

Prigerson HG, Maciejewski PK, Reynolds CF 3rd, Bierhals AJ, Newsom JT, Fasiczka A, Frank E, Doman J, Miller M. Inventory of complicated grief: a scale to measure maladaptive symptoms of loss. Psychiatry Res 1995;59:65–79.PubMedCrossRef

47.

Klaver CC, Wolfs RC, Vingerling JR, Hofman A, de Jong PT. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol 1998;116:653–8.PubMed

48.

Vingerling JR, Hofman A, Grobbee DE, de Jong PT. Age-related macular degeneration and smoking. The Rotterdam Study. Arch Ophthalmol 1996;114:1193–6.PubMed

49.

Vingerling JR, Dielemans I, Bots ML, Hofman A, Grobbee DE, de Jong PT. Age-related macular degeneration is associated with atherosclerosis. The Rotterdam Study. Am J Epidemiol 1995;142:404–9.PubMed

50.

Ikram MK, van Leeuwen R, Vingerling JR, Hofman A, de Jong PT. Relationship between refraction and prevalent as well as incident age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci 2003;44:3778–82.PubMedCrossRef

51.

Klaver CC, Kliffen M, van Duijn CM, et al. Genetic association of apolipoprotein E with age-related macular degeneration. Am J Hum Genet 1998;63:200–6.PubMedCrossRef

52.

Klaver CC, Wolfs RC, Assink JJ, van Duijn CM, Hofman A, de Jong PT. Genetic risk of age-related maculopathy. Population-based familial aggregation study. Arch Ophthalmol 1998;116:1646–51.PubMed

53.

Assink JJ, Klaver CC, Houwing-Duistermaat JJ, et al. Heterogeneity of the genetic risk in age-related macular disease: a population-based familial risk study. Ophthalmology 2005;112:482–7.PubMedCrossRef

54.

van Leeuwen R, Vingerling JR, Hofman A, de Jong PT, Stricker BH. Cholesterol lowering drugs and risk of age related maculopathy: prospective cohort study with cumulative exposure measurement. BMJ 2003;326:255–6.PubMedCrossRef

55.

Despriet DD, Klaver CC, Witteman JC, et al. Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration. JAMA 2006;296:301–9.PubMedCrossRef

56.

Dielemans I, Vingerling JR, Wolfs RC, Hofman A, Grobbee DE, de Jong PT. The prevalence of primary open-angle glaucoma in a population-based study in The Netherlands. The Rotterdam Study. Ophthalmology 1994;101:1851–5.PubMed

57.

Wolfs RC, Borger PH, Ramrattan RS, et al. Changing views on open-angle glaucoma: definitions and prevalences: the Rotterdam Study. Invest Ophthalmol Vis Sci 2000;41:3309–21.PubMed

58.

Dielemans I, Vingerling JR, Algra D, Hofman A, Grobbee DE, de Jong PT. Primary open-angle glaucoma, intraocular pressure, and systemic blood pressure in the general elderly population. The Rotterdam Study. Ophthalmology 1995;102:54–60.PubMed

59.

Wolfs RC, Klaver CC, Ramrattan RS, van Duijn CM, Hofman A, de Jong PT. Genetic risk of primary open-angle glaucoma. Population-based familial aggregation study. Arch Ophthalmol 1998;116:1640–5.PubMed

60.

de Voogd S, Ikram MK, Wolfs RC, Jansonius NM, Hofman A, de Jong PT. Incidence of open-angle glaucoma in a general elderly population: the Rotterdam Study. Ophthalmology 2005;112:1487–93.PubMedCrossRef

61.

Skenduli-Bala E, de Voogd S, Wolfs RC, et al. Causes of incident visual field loss in a general elderly population: the Rotterdam study. Arch Ophthalmol 2005;123:233–8.PubMedCrossRef

62.

Ikram MK, de Jong FJ, Vingerling JR, et al. Are retinal arteriolar or venular diameters associated with markers for cardiovascular disorders? The Rotterdam Study. Invest Ophthalmol Vis Sci 2004;45:2129–34.PubMedCrossRef

63.

Rietveld I, Ikram MK, Vingerling JR, et al. An igf-I gene polymorphism modifies the risk of diabetic retinopathy. Diabetes 2006;55:2387–91.PubMedCrossRef

64.

Ikram MK, de Jong FJ, Bos MJ, et al. Retinal vessel diameters and risk of stroke: the Rotterdam Study. Neurology 2006;66:1339–43.PubMedCrossRef

65.

Ikram MK, Witteman JC, Vingerling JR, Breteler MM, Hofman A, de Jong PT. Retinal vessel diameters and risk of hypertension: the Rotterdam Study. Hypertension 2006;47:189–94.PubMedCrossRef

66.

Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 1995;39:367–74.PubMedCrossRef

67.

Hubbard LD, Brothers RJ, King WN, et al. Methods for evaluation of retinal microvascular abnormalities associated with hypertension/sclerosis in the Atherosclerosis Risk in Communities Study. Ophthalmology 1999;106:2269–80.PubMedCrossRef

68.

van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, van der Klift M, de Jonge R, Lindemans J, de Groot LC, Hofman A, Witteman JC, van Leeuwen JP, Breteler MM, Lips P, Pols HA, Uitterlinden AG. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 2004;350:2033–41.PubMedCrossRef

69.

Vaessen N, Janssen JA, Heutink P, Hofman A, Lamberts SW, Oostra BA, Pols HA, van Duijn CM. Association between genetic variation in the gene for insulin-like growth factor-I and low birthweight. Lancet 2002;359:1036–7.PubMedCrossRef

70.

van Meurs JBJ, Schuit SCE, Weel AEAM, van der Klift M, Bergink AP, Arp PP, Colin EM, Fang Y, Hofman A, van Duijn CM, van Leeuwen JPTM, Pols HAP, Uitterlinden AG. Association of 5′ estrogen receptor alpha gene polymorphisms with bone mineral density, vertebral bone area, and fracture risk. Hum Mol Genet 2003;12:1745–54.PubMedCrossRef

71.

Despriet DD, Klaver CC, Witteman JC, Bergen AA, Kardys I, de Maat MP, Boekhoorn SS, Vingerling JR, Hofman A, Oostra BA, Uitterlinden AG, Stijnen T, van Duijn CM, de Jong PT. Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration. JAMA 2006;296:301–9.PubMedCrossRef

72.

Aarnoudse AJLHJ, Newton-Cheh C, de Bakker PIW, Straus SMJM, Kors JA, Hofman A, Uitterlinden AG, Witteman JCM, Stricker BHCh. A common NOS1AP variant is associated with longer QTc interval and sudden cardiac death: the Rotterdam Study. Circulation 2007;116:10–6.

73.

Fang Y, van Meurs JB, d’Alesio A, Jhamai M, Zhao H, Rivadeneira F, Hofman A, van Leeuwen JP, Jehan F, Pols HA, Uitterlinden AG. Promoter and 3′ UTR haplotypes in the vitamin D receptor gene predispose to osteoporotic fracture: the Rotterdam Study Am J Hum Genet 2005;77:807–23.PubMedCrossRef

74.

Aulchenko YS, Ripke S, Isaacs A, van Duijn CM. GenABEL: an R library for genome-wide association analysis. Bioinformatics 2007 (in press).

75.

In ‘t Veld BA, Ruitenberg A, Hofman A, Stricker BHCh, Breteler MMB. Antihypertensive drugs and incidence of dementia: the Rotterdam study. Neurobiol Aging 2001;22:407–12.

76.

Feenstra J, Heerdink ER, Grobbee DE, Stricker BHCh. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure. Arch Int Med 2002;162:265–70.CrossRef

77.

Straus SM, Kors JA, de Bruin ML, van der Hooft CS, Hofman A, Heeringa J, Deckers JW, Kingma JH, Sturkenboom JCM, Stricker BHCh, Witteman JCM. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol 2006;47:362–7.PubMedCrossRef

78.

Van der Hooft CS, Heeringa J, Brusselle GG, Hofman A, Witteman JCM, Kingma JH, Sturkenboom MCJM, Stricker BHCh. Corticosteroids and the risk of atrial fibrillation. Arch Int Med 2006;165:1016–20.CrossRef

79.

Schoofs MWCJ, van der Klift M, Hofman A, de Laet CEDH, Herings RMC, Stijnen Th, Pols HAP, Stricker BHCh. Thiazide diuretics and the risk for hip fracture. Ann Intern Med 2003;139:476–82.PubMed

80.

Schoofs MW, Sturkenboom MCJM, van der Klift M, Hofman A, Pols HA, Stricker BHCh. HMG-CoA reductase inhibitors and the risk of vertebral fracture. J Bone Miner Res 2004;19:1525–30.PubMedCrossRef

81.

Reijman M, Bierma-Zeinstra SM, Pols HAP, Koes BW, Stricker BHCh, Hazes JM. Is there an association between the use of different types of NSAIDs and radiologic progression of osteoarthritis ? The Rotterdam Study. Arthritis Rheum 2005;52:3137–42.PubMedCrossRef

82.

Van Leeuwen R, Vingerling JR, Hofman A, de Jong PTVM, Stricker BHCh. Cholesterol lowering drugs and risk of age related maculopathy: prospective cohort study with cumulative exposure measurement. BMJ 2003;326:255–6.PubMedCrossRef

83.

Visser LE, Penning-van Beest FJA, Kasbergen AAH, De Smet PAGM, Vulto AG, Hofman A, Stricker BHCh. Overanticoagulation associated with combined use of antifungal agents and coumarin anticoagulants. Clin Pharmacol Ther 2002;71:496–502.PubMedCrossRef

84.

Visser LE, Penning-van Beest FJA, Kasbergen HAA, De Smet PAGM, Vulto AG, Hofman A, Stricker BHCh. Overanticoagulation associated with combined use of antibacterial agents and acenocoumarol or phenprocoumon anticoagulants. Thromb Haemost 2002;88:705–10.PubMed

85.

Visser LE, van Vliet M, van Schaik RHN, Kasbergen AAH, de Smet PAGM, Vulto AG, Hofman A, van Duijn CM, Stricker BHCh. The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics 2004;14:27–33.PubMedCrossRef

86.

Visser LE, Penning-van Beest FJ, Wilson JHP, Vulto AG, Kasbergen AA, de Smet PAGM, Hofman A, Stricker BHCh. Overanticoagulation associated with combined use of lactulose and coumarin anticoagulants. Br J Clin Pharmacol 2004;57:522–4.PubMedCrossRef

87.

Visser LE, van Schaik RH, van Vliet M, Trienekens PH, de Smet PAGM, Vulto AG, Hofman A, van Duijn CM, Stricker BHCh. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thromb Haemost 2004;92:61–6.PubMed

88.

Visser LE, Bleumink GS, Trienekens PH, Vulto AG, Hofman A, Stricker BHCh. The risk of overanticoagulation in patients with heart failure on coumarin anticoagulants. Br J Haematol 2004;127:85–9.PubMedCrossRef

89.

Visser LE, van Schaik RHN, van Vliet M, Trienekens PH, de Smet PAGM, Vulto AG, Hofman A, van Duijn CM, Stricker BHCh. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants. Clin Pharmacol Ther 2005;77:479–85.PubMedCrossRef

90.

Bleumink GS, Schut AF, Sturkenboom MC, van Duijn CM, Deckers JW, Hofman A, Kingma JH, Witteman JC, Stricker BHCh. Mortality in patients with hypertension on ACE-inhibitor treatment is influenced by the ACE I/D polymorphism. Pharmacogenet Genomics 2005;15:75–81.PubMedCrossRef

91.

Visser LE, Trienekens PH, de Smet PAGM, Vulto AG, Hofman A, van Duijn CM, Stricker BHCh. Patients with an ApoE epsilon4 allele require lower doses of coumarin anticoagulants. Pharmacogenet Genomics 2005;15:69–74.PubMedCrossRef

Title: The Rotterdam Study: objectives and design update
Authors: Albert Hofman
Monique M. B. Breteler
Cornelia M. van Duijn
Gabriel P. Krestin
Huibert A. Pols
Bruno H. Ch. Stricker
Henning Tiemeier
André G. Uitterlinden
Johannes R. Vingerling
Jacqueline C. M. Witteman
Publication date: 01-11-2007
Publisher: Springer Netherlands
Published in: European Journal of Epidemiology / Issue 11/2007
Print ISSN: 0393-2990
Electronic ISSN: 1573-7284
DOI: https://doi.org/10.1007/s10654-007-9199-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The Rotterdam Study: objectives and design update

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2007

Forty-year coronary mortality trends and changes in major risk factors in the first 10 years of follow-up in the seven countries study

Case-control study of environmental and social factors influencing cryptosporidiosis

Study of partner-related and situational risk factors for symptomatic male urethritis

Acute myocardial infarction incidence and hospital mortality: routinely collected national data versus linkage of national registers

HIV incidence estimate among non-nationals in Italy

Sodium and potassium intake and risk of cardiovascular events and all-cause mortality: the Rotterdam Study